Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer
Results from the Phase 2 I-SPY2.2 SMART
Results from the Phase 2 I-SPY2.2 SMART
Rebecca Shatsky, MD, University of California, San Diego, La Jolla, California, discusses results from the multicenter, phase 2 I-SPY2.2 trial, a platform sequential multiple assignment randomized trial (SMART), evaluating novel experimental neoadjuvant regimens for breast cancer. These results show pCR rates of patients who received datopotamab deruxtecan plus durvalumab.
The regimen of datopotamab deruxtecan and durvalumab reached the threshold for graduation within the tumor response predictive subtype group including patients predicted to have a good sensitive to immunotherapy, with an estimated pCR rate of 0.72.
Transcript:
Transcript to come.
Source:
Shatsky RA, Trivedi MS, Omene CO, et al. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. Presented at the 2024 ASCO Annual Meeting. May 31-June 4, 2024; Chicago, IL. Abstract #LBA501
